ProShare Advisors LLC Grows Position in Cencora, Inc. (NYSE:COR)

ProShare Advisors LLC grew its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 6.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,669 shares of the company's stock after buying an additional 2,304 shares during the quarter. ProShare Advisors LLC's holdings in Cencora were worth $8,688,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of COR. Price T Rowe Associates Inc. MD boosted its position in Cencora by 0.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock valued at $1,990,542,000 after buying an additional 78,066 shares during the period. Bank of America Corp DE boosted its holdings in shares of Cencora by 62.3% during the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock worth $1,166,944,000 after purchasing an additional 1,994,256 shares during the period. Boston Partners boosted its holdings in shares of Cencora by 2.6% during the fourth quarter. Boston Partners now owns 5,007,100 shares of the company's stock worth $1,128,058,000 after purchasing an additional 125,611 shares during the period. Geode Capital Management LLC grew its stake in shares of Cencora by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock worth $969,471,000 after purchasing an additional 130,213 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Cencora by 20.4% during the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after purchasing an additional 550,246 shares during the period. 97.52% of the stock is owned by institutional investors.

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This represents a 24.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. The trade was a 21.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock valued at $13,580,967 in the last 90 days. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Down 0.5%

Shares of NYSE:COR traded down $1.50 during midday trading on Wednesday, reaching $291.43. The company's stock had a trading volume of 942,182 shares, compared to its average volume of 1,545,004. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a 50 day moving average of $281.28 and a 200-day moving average of $256.26. The firm has a market capitalization of $56.49 billion, a P/E ratio of 41.46, a PEG ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the firm posted $3.80 earnings per share. Cencora's quarterly revenue was up 10.3% on a year-over-year basis. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a $0.55 dividend. The ex-dividend date is Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. Cencora's payout ratio is currently 25.52%.

Wall Street Analysts Forecast Growth

COR has been the subject of several research analyst reports. Morgan Stanley set a $288.00 price objective on Cencora in a report on Tuesday, April 15th. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Robert W. Baird boosted their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Finally, StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $301.18.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.